EUVIMEDEUVIMED entdecken
Crossref

Pharmaceutical Development Challenges in a Beyond Rule of Five Prodrug: Case Study of ABBV-167, Phosphate Prodrug of Venetoclax

Richard Hong, Haichen Nie, Rodger F Henry, Sean M Garner, Nathaniel D Catron, Russell L Hertzler, Andrew J Souers, Ahmad Y Sheikh iD, Shuang Chen iD

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Richard Hong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research & Development, AbbVie Inc., North Chicago, Illinois 60064, United States. Hauptthemen laut MEDLINE: Prodrugs. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ABBV-167, a phosphate prodrug of BCL-2 inhibitor venetoclax, was recently progressed into the clinic as an alternative means of reducing pill burden for patients in high-dose indications. The dramatically enhanced aqueous solubility of ABBV-167 allowed for high drug loading within a crystalline tablet and, when administered in phase I clinical study, conferred venetoclax exposure commensurate with the equivalent dose administered as an amorphous solid dispersion. In enabling the progression into the clinic, we performed a comprehensive evaluation of the CMC development aspects of this beyond the rule of five (bRo5) prodrug. Adding a phosphate moiety resulted in excessively complex chemical speciation and solid form landscapes with significant physical-chemical stability liabilities. A combination of experimental and computational methods including microelectron diffraction (MicroED), total scattering, tablet colorimetry, finite element, and molecular dynamics modeling were used to understand CMC developability across drug substance and product manufacture and storage. The prodrug's chemical structural characteristics and loose crystal packing were found to be responsible for the loss of crystallinity during its manufacturing, which in turn led to high solid-state chemical reactivity and poor shelf life stability. The ABBV-167 case exemplifies key CMC development challenges for complex chemical matter such as bRo5 phosphate prodrugs with significant ramifications during drug substance and drug product manufacturing and storage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsHumansPhosphatesDrug DevelopmentSolubilityTabletsSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

beyond rule of fivecompactioncrystallinitydryingfinite element analysishydratemicroelectron diffractionphosphate prodrugstabilitytotal scatteringvenetoclax

Substanzen

ProdrugsPhosphatesTabletsvenetoclaxSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Research & Development, AbbVie Inc., North Chicago, Illinois 60064, United States.

ORCID-Profile: Ahmad Y Sheikh, Shuang Chen

Zitieren

APA

Hong, R., Nie, H., Henry, R. F., Garner, S. M., Catron, N. D., Hertzler, R. L., Souers, A. J., Sheikh, A. Y., & Chen, S. (2023). Pharmaceutical Development Challenges in a Beyond Rule of Five Prodrug: Case Study of ABBV-167, Phosphate Prodrug of Venetoclax. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00675

Vancouver

Hong R, Nie H, Henry RF, Garner SM, Catron ND, Hertzler RL, et al. Pharmaceutical Development Challenges in a Beyond Rule of Five Prodrug: Case Study of ABBV-167, Phosphate Prodrug of Venetoclax. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00675

BibTeX
@article{Hong2023,
  author = {Hong, Richard and Nie, Haichen and Henry, Rodger F and Garner, Sean M and Catron, Nathaniel D and Hertzler, Russell L and Souers, Andrew J and Sheikh, Ahmad Y and Chen, Shuang},
  title = {Pharmaceutical Development Challenges in a Beyond Rule of Five Prodrug: Case Study of ABBV-167, Phosphate Prodrug of Venetoclax},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00675}
}
Kostenlos starten →